Posted by Michael Wonder on 17 Apr 2023
AbbVie announces European Commission approval of Rinvoq (upadacitinib) for the treatment of moderately to severely active Crohn's disease
17 April 2023 - Seventh approved indication for Rinvoq in the European Union and the first and only oral janus kinase inhibitor approved to treat adult patients with moderately to severely active Crohn's disease.
AbbVie today announced the European Commission approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral janus kinase inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
